Certa Therapeutics is a biotechnology company dedicated to transforming the lives of patients battling challenging and often life-threatening chronic diseases. With a focus on inflammatory and fibrotic diseases, we develop innovative precision treatments backed by scientific excellence. Our groundbreaking class of drugs holds the potential to revolutionize the treatment of serious conditions such as systemic sclerosis, chronic kidney disease, focal segmental glomerulosclerosis, diabetic retinopathy, and more.

By advancing these novel therapeutics through clinical development, we aim to provide precision medicine treatments for these conditions. Our platform of candidate drugs, along with the identification of a novel receptor that mediates inflammation and fibrosis signaling pathways, sets us apart. We collaborate closely with fellow Australian biotech company OccuRx to develop a treatment platform for a range of inflammatory and fibrotic diseases.

Supported by esteemed investment partners, Certa Therapeutics is driven by a shared mission to make a lasting impact in this field. Visit our website to learn more about our innovative approach and our commitment to improving lives